健帆生物科技集团股份有限公司 2021 年第三季度报告 健帆生物科技集团股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导 性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真 实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 会计政策变更 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------|----------------|-------------------|----------------|------- ...

Financial Performance - The company's operating revenue for the reporting period was ¥1,188,254,809.14, representing a 36.63% increase compared to the previous year[13]. - The net profit attributable to shareholders was ¥620,140,698.34, reflecting a 40.74% year-over-year growth[13]. - The net profit after deducting non-recurring gains and losses was ¥584,793,617.60, up by 40.28% from the same period last year[13]. - The net cash flow from operating activities reached ¥492,315,765.05, marking a 44.88% increase compared to the previous year[13]. - The total assets at the end of the reporting period were ¥4,491,865,044.04, a 38.95% increase from the end of the previous year[13]. - The weighted average return on net assets was 22.94%, an increase of 3.85% compared to the previous year[13]. - The company's revenue for the reporting period reached ¥1,188,254,809.14, a year-on-year increase of 36.63% driven by enhanced market promotion and R&D investment[57]. - The net profit for the period was ¥619,052,068.06, reflecting a 40.93% increase year-on-year, primarily due to increased sales revenue[57]. - The total liabilities amounted to ¥1,264,404,250.38, significantly up from ¥383,060,209.90 at the end of 2020, representing a rise of approximately 230.66%[135]. Research and Development - Future outlook indicates a commitment to research and development of new products and technologies, enhancing its competitive edge[6]. - Research and development investment during the reporting period was 51.17 million yuan, accounting for 4.31% of total operating revenue, with a year-on-year growth of 65.62%[43]. - The company adopts a combined research and development model, focusing on independent and joint R&D to enhance efficiency and reduce risks, collaborating with institutions like the Chinese Academy of Sciences and several universities[24][25]. - The company obtained 5 invention patents, 12 utility model patents, and 5 design patents during the first half of 2021, with a total of 221 authorized patents by the end of the reporting period[43]. - The company has a strong R&D team with 197 master's and 9 doctoral degree holders, covering various fields related to medical engineering[42]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies, including potential mergers and acquisitions[6]. - The company has established several subsidiaries to enhance its operational capabilities and market reach[4]. - The company has established a marketing network covering over 5,900 hospitals nationwide, with more than 4,500 promotional activities conducted in the uremia field during the reporting period[48]. - The company has formed an overseas expert committee to enhance the global application of its blood adsorption therapy, collaborating with top international experts[49]. - The company aims to leverage its technological advantages and strong marketing capabilities to continuously develop a series of blood purification products targeting critical diseases[39]. Product Performance - The sales revenue from disposable blood perfusion devices was ¥1,048,501,200, accounting for 88.33% of the company's main business income, with a year-over-year growth of 32.85%[19]. - The sales revenue from disposable plasma bilirubin adsorbers was ¥61,537,200, representing 5.18% of the main business income, with an impressive growth of 82.95%[20]. - The DX-10 blood purification machine generated sales revenue of ¥26,733,100, which is 2.25% of the main business income, showing a significant increase of 162.42%[21]. - The sales revenue of the blood dialysis powder liquid products reached 21.0183 million yuan, accounting for 1.77% of the company's main business income, with a year-on-year growth of 71.68%[23]. - The company’s HA380 blood perfusion device achieved sales revenue of 18.17 million yuan, with a remarkable year-on-year growth of 1157.88% in the critical care field[49]. Corporate Governance and Compliance - The financial report emphasizes the importance of accurate and complete financial disclosures, ensuring transparency[1]. - The board of directors and management have confirmed the authenticity and completeness of the financial report[1]. - The company has obtained a total of 17 medical device registration certificates, with 4 new additions since the end of 2020, demonstrating its commitment to compliance and product development[39]. - The company has developed a systematic quality control capability, ensuring compliance with ISO13485 standards since 2005[45]. - The company has established a strict quality control system, ensuring compliance with national standards and has not experienced any medical incidents due to product quality issues since its inception[85]. Social Responsibility - The company is committed to fulfilling its social responsibilities and adhering to environmental standards[6]. - The company actively participated in social responsibility initiatives, donating 5 million CNY to the China Hepatitis Prevention Foundation and 3 million CNY in medical supplies to flood-affected areas[93]. Financial Management - The company completed the issuance of convertible bonds, resulting in a net cash inflow from financing activities of ¥656,964,138.06, a 342.98% increase year-on-year[57]. - The total cash inflow from financing activities was CNY 1,187,979,656.94, a significant increase of 926.58% due to the issuance of convertible bonds[58]. - The company has engaged in entrusted financial management, with a total of RMB 120 million allocated to bank and brokerage financial products, all of which are currently not overdue[78]. - The company reported a loss of ¥34,783.87 from its investments during the reporting period[66]. - The company has not changed the use of raised funds, with a cumulative change ratio of 0.00%[72]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 36,701[115]. - The largest shareholder, Dong Fan, holds 43.58% of the shares, totaling 350,828,772 shares[117]. - The company did not conduct any repurchase transactions among the top ten ordinary shareholders during the reporting period[118]. - The total number of shares held by the top ten shareholders includes significant holdings by Hong Kong Central Clearing Limited (3.85%) and Tang Xianmin (2.64%)[117]. - The company confirmed that there are no arrangements for differential voting rights among shareholders[118]. Operational Highlights - The company has maintained its registered address and contact information without changes during the reporting period[8]. - The company did not distribute cash dividends or bonus shares for the first half of 2021[89]. - The company has not sold any significant assets or equity during the reporting period, indicating stability in its asset management[81][82]. - The company did not engage in any major related party transactions during the reporting period[102]. - The company has no derivative investments or entrusted loans reported during the period, reflecting a conservative financial strategy[79][80].

证券代码：300529 证券简称：健帆生物 公告编号：2021-057 健帆生物科技集团股份有限公司 关于参加 2021 年广东上市公司投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 为进一步加强与投资者的交流沟通，健帆生物科技集团股份有限公司（以下简 称"公司"）将参加由广东证监局、广东上市公司协会共同举办的"心系投资者，携 手共行动——守初心、担使命、为投资者办实事"——2021 年广东上市公司投资者网 上集体接待日活动"。现将有关事项公告如下： 本次投资者集体接待日活动将在深圳市全景网络有限公司提供的网上平台、采 取网络远程的方式举行，投资者可以登录"全景•路演天下"网站（http://rs.p5w.net）参 与公司本次投资者集体接待日活动，活动时间为 2021 年 5 月 19 日（星期三）15:40 至 16:40。 届时公司董事会秘书张明渊先生将通过网络在线方式，与投资者就公司治理、 经营情况及发展战略等问题进行沟通与交流，欢迎广大投资者积极参与。 特此公告。 健帆生物科技集团股份有限公司董事会 2021 年 5 ...

健帆生物科技集团股份有限公司 2021 年第一季度报告全文 健帆生物科技集团股份有限公司 2021 年第一季度报告 2021 年 04 月 1 健帆生物科技集团股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人董凡、主管会计工作负责人何小莲及会计机构负责人(会计主管 人员)李紫芸声明：保证季度报告中财务报表的真实、准确、完整。 2 健帆生物科技集团股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|--------------- ...

Financial Performance - The company's operating revenue for 2020 was ¥1,950,780,490.05, representing a 36.24% increase compared to ¥1,431,819,390.39 in 2019[12]. - The net profit attributable to shareholders for 2020 was ¥875,240,536.84, a 53.33% increase from ¥570,822,715.83 in 2019[12]. - The net profit excluding non-recurring gains and losses for 2020 was ¥840,944,452.67, reflecting a 61.10% increase from ¥521,987,891.57 in 2019[12]. - The company's cash flow from operating activities for 2020 was ¥957,488,770.47, up 64.10% from ¥583,495,276.06 in 2019[12]. - The total assets at the end of 2020 were ¥3,216,670,261.94, a 28.94% increase from ¥2,494,662,121.83 at the end of 2019[12]. - The basic earnings per share for 2020 were ¥1.10, a 52.78% increase from ¥0.72 in 2019[12]. - The weighted average return on net assets for 2020 was 35.74%, an increase of 5.50% from 30.24% in 2019[12]. - The total revenue for 2020 reached ¥1,950,780,490.05, representing a year-on-year increase of 36.24% compared to ¥1,431,819,390.39 in 2019[72]. - The revenue from the medical device manufacturing sector was ¥1,942,329,899.08, accounting for 99.57% of total revenue, with a year-on-year growth of 35.90%[72]. - The gross profit margin for the medical device manufacturing sector was 85.67%, with a slight decrease of 0.52% from the previous year[73]. Product Development and Market Expansion - The company reported a significant focus on R&D in blood purification technologies, which are critical for treating severe liver diseases with mortality rates exceeding 70%[6]. - The company emphasizes the importance of CRRT (Continuous Renal Replacement Therapy) as a vital support measure in treating critically ill patients, highlighting its growing relevance in clinical settings[6]. - The company has expanded its product offerings to over 5,800 hospitals across the country, enhancing its brand influence and sales growth[19]. - The company has established a stable and growing market demand for its standardized medical consumables, with production plans based on sales targets and inventory levels[29]. - The company aims to continuously innovate in its research areas, maintaining a leading position in domestic and advanced international technology[25]. - The company plans to expand into new market segments such as severe liver disease and cardiac surgery, while also pursuing overseas market growth[98]. - The company is actively promoting its artificial liver technology and has plans for overseas market expansion[113]. - The company achieved a sales revenue of 1,272.82 million yuan from HA130 blood perfusion devices, representing a year-on-year growth of 31.43%[50]. - The company’s overseas market sales reached 53.70 million yuan, marking a significant year-on-year increase of 193.98%[55]. Research and Development - The company invested CNY 80.76 million in R&D, accounting for 4.14% of total revenue, with a year-on-year growth of 17.98%[44]. - The company applied for 48 new patents during the reporting period, with 4 invention patents and 14 utility models granted[44]. - The company has over 300 process documents and nearly 200 quality control documents to ensure strict quality management of its blood perfusion products[29]. - The company collaborates with various research institutions for joint research and development to enhance its technological capabilities in the blood perfusion industry[26]. - The company aims to develop a series of blood purification products targeting critical and difficult diseases, focusing on inflammation mediators, immunity, bilirubin, endotoxins, and blood lipid reduction[99]. Corporate Governance and Management - The company has established a comprehensive corporate governance structure and effective regulations to support its growth[112]. - The company has implemented a stock incentive plan, with 1,030,050 stock options granted to 184 participants in the second exercise period[131]. - The company has a well-structured governance framework, including a shareholders' meeting, board of directors, and supervisory board, with no institutional overlap with controlling shareholders[197]. - The company maintains independence from its controlling shareholder in terms of business operations, assets, and financial matters[189]. - The company’s board of directors consists of 9 members, including 3 independent directors, enhancing decision-making capabilities[190]. Social Responsibility - The company donated over CNY 20 million in cash and medical supplies to support frontline healthcare workers during the COVID-19 pandemic[49]. - The company has cumulatively donated ¥4.06 million through the "Guangdong Poverty Alleviation Day" initiative since 2017[67]. - The company donated 2,000,000 CNY in cash and 8,850,000 CNY in medical supplies to support COVID-19 efforts, including blood purification devices[143]. - The company received a special contribution award for its efforts in combating the pandemic from the Zhuhai Economic Cooperation Association[143]. Risks and Challenges - The company faces market risks due to a high reliance on single-use blood perfusion devices, which may limit future growth if market demand does not meet expectations[105]. - The company is at risk of increased competition in the blood perfusion device market, which could lead to price reductions and impact future profitability[106]. - The company’s revenue is heavily dependent on single-use blood perfusion devices, making it vulnerable to changes in policy or technology that could affect production and sales[109]. - The company’s high gross margin may decline if it fails to adapt to technological advancements and competitive dynamics in the rapidly developing blood purification sector[110]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 36,529, an increase from 33,626 at the end of the previous month[159]. - The largest shareholder, Dong Fan, holds 43.90% of the shares, totaling 350,828,772 shares, with a decrease of 152,489,159 shares during the reporting period[159]. - The company’s shareholder structure and asset-liability structure have undergone changes, but specific details were not disclosed in the report[157]. - The total shares held by the chairman and general manager, Dong Fan, increased from 198,339,613 to 350,828,772, reflecting an increase of 76.7%[166]. Future Outlook - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% to $625 million[176]. - Market expansion plans include entering three new international markets by Q3 2024, targeting a 30% increase in global market share[176]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of $100 million set aside for this purpose[176].

Financial Performance - Net profit attributable to shareholders increased by 66.54% to CNY 186,780,990.40 for the reporting period[3] - Operating revenue for the reporting period reached CNY 445,657,614.95, representing a 42.64% increase year-on-year[3] - Basic earnings per share rose by 65.74% to CNY 0.2337 for the reporting period[3] - The company's total revenue for the year reached ¥1,315,332,870.12, representing a 35.42% increase compared to ¥971,272,392.55 in the same period last year[11] - The net profit for the period was ¥625,716,200.23, a 50.16% increase from ¥416,694,208.51 in the previous year[12] - The company reported a total profit of ¥220,657,263.47 for the current period, compared to ¥133,318,266.82 in the previous period, which is an increase of approximately 65.5%[28] - The company’s total comprehensive income for the current period was ¥186,442,515.37, compared to ¥111,627,385.18 in the previous period, indicating a growth of about 67.0%[30] - Net profit attributable to the parent company was ¥627,410,475.05, up 50.1% from ¥417,913,065.45 year-on-year[35] Assets and Liabilities - Total assets increased by 15.01% to CNY 2,869,093,935.58 compared to the end of the previous year[3] - The total assets of the company showed a significant increase, with inventories rising by 31.35% to ¥121,258,864.78, reflecting higher stock levels of finished goods and raw materials[10] - Non-current assets totaled CNY 1,112,646,688.26, compared to CNY 934,918,357.17 in the previous year, indicating an increase of about 19%[20] - Current liabilities decreased to CNY 233,967,719.50 from CNY 262,633,102.43, a reduction of approximately 11%[21] - The total liabilities amounted to 324,127,383.83 CNY, remaining stable compared to the previous year[49] - The company’s total current liabilities included accounts payable of CNY 25,640,615.34 and employee compensation payable of CNY 63,417,784.03[51] Cash Flow - The net cash flow from operating activities was CNY 154,752,965.10, up 21.97% compared to the same period last year[3] - Cash received from other operating activities amounted to ¥124,925,583.51, reflecting a 56.13% increase year-over-year[13] - The net cash flow from investment activities was -¥626,115,343.34, an improvement of 44.79% compared to the previous year[13] - The total cash and cash equivalents at the end of the period stood at CNY 868.38 million, significantly up from CNY 132.87 million at the end of the previous year[43] - The net cash flow from financing activities was negative CNY 266.80 million, worsening from negative CNY 195.44 million year-over-year[43] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,656[6] - The largest shareholder, Dong Fan, holds 43.90% of the shares, totaling 350,828,772 shares[6] Government Support - The company received government subsidies amounting to CNY 38,113,196.22 during the reporting period[4] - The company received tax refunds totaling ¥368,207.06, an increase of 121.44% compared to the previous year[13] Research and Development - Research and development expenses for the current period were ¥17,434,484.62, slightly down from ¥17,479,018.30 in the previous period, showing a decrease of about 0.3%[27] - Research and development expenses were ¥48,328,844.23, slightly up from ¥47,361,568.24, indicating continued investment in innovation[34] Compliance and Regulatory - The company has not reported any non-compliance issues or overdue commitments during the reporting period[16] - The company has received inquiries regarding its application for issuing convertible bonds, indicating ongoing regulatory engagement[15] Future Plans - The company plans to issue convertible bonds totaling up to ¥1 billion, approved by the board and shareholders[15] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[36]

Financial Performance - The company reported a revenue of RMB 300 million for the first half of 2020, representing a year-on-year increase of 25%[6]. - The gross profit margin improved to 60%, up from 55% in the same period last year[6]. - The company aims to achieve a revenue target of RMB 600 million for the full year 2020, reflecting a growth rate of 20%[6]. - The company reported a net profit of RMB 80 million for the first half of 2020, a 10% increase compared to the same period last year[6]. - The company's operating revenue for the reporting period was ¥869,675,255.17, representing a 32.00% increase compared to ¥658,847,826.73 in the same period last year[11]. - The net profit attributable to shareholders was ¥440,629,484.65, up 44.11% from ¥305,761,632.34 year-on-year[11]. - The net profit after deducting non-recurring gains and losses was ¥416,865,727.52, reflecting a 53.17% increase from ¥272,150,992.49 in the previous year[11]. - The net cash flow from operating activities was ¥339,816,527.36, an increase of 33.39% compared to ¥254,748,802.25 in the same period last year[11]. - The company reported a net profit margin of 12% for the first half of 2020, an increase from 10% in the previous year[150]. Research and Development - The company plans to invest RMB 50 million in R&D for new product development in the next fiscal year[6]. - The company's revenue for the reporting period was CNY 30.1 million, with a year-on-year growth of 3.55% in R&D investment, amounting to CNY 3.09 million[26]. - The company employs a dual research and development model, combining independent and collaborative efforts with institutions like the Chinese Academy of Sciences[20]. - The company’s research focuses on key areas such as carrier preparation theory and technology, achieving a leading position domestically and internationally[20]. - The company has developed a new dual plasma molecular adsorption system (DPMAS) for liver disease treatment, which has been recognized in several medical guidelines[23]. - The company obtained 13 new patents in the first half of 2020, including 8 utility models and 5 design patents[33]. - The company holds 203 authorized patents, including 41 invention patents, with a focus on innovative blood purification technologies[26]. Market Expansion - User data indicates a 30% increase in the number of active users of the company's medical devices compared to the previous year[6]. - The company has expanded its market presence by entering three new provinces in China, increasing its distribution network by 20%[6]. - The company has launched a new blood purification technology that is expected to increase market share by 15%[6]. - The company is exploring potential acquisitions in the biotechnology sector to enhance its product portfolio[6]. - The company plans to continue expanding its market presence and investing in new product development to sustain growth[104]. - Market expansion plans include entering two new international markets by the end of 2020, which is anticipated to increase market share by 5%[150]. - The company completed a strategic acquisition of a competitor, which is expected to enhance its product offerings and increase revenue by 30% in the next fiscal year[150]. Production and Quality Control - The company maintains a safety stock of approximately two months to meet market demand, with all products being self-manufactured[21]. - The company has established over 300 process documents and nearly 200 quality control documents to ensure strict product quality control[21]. - The company emphasizes strict quality control for its blood purification products, which are classified as Class III medical devices[59]. - The company faces risks related to product quality control, single product structure, and potential declines in gross margin[59]. Financial Position and Investments - The total assets at the end of the reporting period were ¥2,725,908,619.99, a 9.27% increase from ¥2,494,662,121.83 at the end of the previous year[11]. - The company has a strong market position in blood purification technology, with no significant competitive pressure identified in the market[23]. - The company has committed CNY 50,000,000 to bank wealth management products, with no overdue amounts[54]. - The company made a significant equity investment of CNY 100,000,000.00 in Zhuhai Jianhang Medical Technology Co., Ltd., acquiring a 100% stake[50]. - The company is investing approximately RMB 1.5 billion in a blood purification project in Zhuhai, which is expected to expand production capacity significantly, with an anticipated annual revenue exceeding RMB 1.6 billion upon reaching full capacity[37]. Shareholder and Equity Information - The company has implemented four stock incentive plans since its listing in 2016, covering 729 employees and allowing 129 out of 188 eligible individuals to fully unlock their restricted stocks in 2020[34]. - The company distributed a cash dividend of RMB 0.90 per share (including tax) and increased share capital by 90% through capital reserve conversion[79]. - The company has a total of 26,901 shareholders at the end of the reporting period, with 10 shareholders holding restricted shares[83]. - The largest shareholder, Dong Fan, holds 43.90% of the shares, totaling 350,828,772 shares, with a reduction of 152,489,159 shares during the reporting period[83]. Corporate Governance and Compliance - The financial report for the first half of 2020 was not audited[94]. - The company has not engaged in any significant related party transactions during the reporting period[69]. - There were no major litigation or arbitration matters during the reporting period[66]. - The company has not been classified as a key pollutant discharge unit by environmental protection authorities[75]. Future Outlook - The company provided a positive outlook for the next quarter, projecting a revenue growth of 20% based on current market trends[150]. - New product launches are expected to contribute an additional $10 million in revenue in the upcoming quarter[150]. - The company plans to implement cost-cutting measures aimed at reducing operational expenses by 8% in the next quarter[150].

证券代码：300529 证券简称：健帆生物 公告编号：2020-066 健帆生物科技集团股份有限公司 关于参加 2020 年广东辖区上市公司投资者集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 为进一步加强与投资者的交流沟通，健帆生物科技集团股份有限公司（以下简 称"公司"）将参加由广东证监局、广东上市公司协会共同举办的"心系股东，做受尊 敬的上市公司——2020 年广东辖区上市公司投资者集体接待日"活动。现将有关事项 公告如下： 本次投资者集体接待日活动将在深圳市全景网络有限公司提供的网上平台、采 取网络远程的方式举行，投资者可以登录"全景•路演天下"网站（http://rs.p5w.net）参 与公司本次投资者集体接待日活动，活动时间为 2020 年 5 月 18 日（星期一）15:50 至 16:50。 届时公司董事会秘书张明渊先生将通过网络在线方式，与投资者就公司治理、 经营情况及发展战略等问题进行沟通与交流，欢迎广大投资者积极参与。 特此公告。 健帆生物科技集团股份有限公司董事会 2020 年 5 月 15 日 1 ...

健帆生物科技集团股份有限公司 2020 年第一季度报告全文 1 健帆生物科技集团股份有限公司 2020 年第一季度报告 2020 年 04 月 健帆生物科技集团股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人董凡、主管会计工作负责人董凡及会计机构负责人(会计主管人 员)何小莲声明：保证季度报告中财务报表的真实、准确、完整。 2 健帆生物科技集团股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|--------------------------| | □ 是 √ 否 | ...

Financial Performance - The company's operating revenue for 2019 was CNY 1,431,819,390.39, representing a 40.86% increase compared to CNY 1,016,508,792.15 in 2018[13]. - The net profit attributable to shareholders for 2019 was CNY 570,822,715.83, up 42.00% from CNY 401,979,957.01 in 2018[13]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 521,987,891.57, reflecting a 48.19% increase from CNY 352,240,444.88 in 2018[13]. - The net cash flow from operating activities for 2019 was CNY 583,495,276.06, a 51.92% increase compared to CNY 384,076,786.14 in 2018[13]. - The basic earnings per share for 2019 was CNY 1.38, an increase of 42.27% from CNY 0.97 in 2018[13]. - The total assets at the end of 2019 were CNY 2,494,662,121.83, which is a 21.57% increase from CNY 2,051,958,224.36 at the end of 2018[13]. - The net assets attributable to shareholders at the end of 2019 were CNY 2,142,470,110.80, up 26.14% from CNY 1,698,478,517.26 at the end of 2018[13]. - The company reported a total of CNY 31,655,056.05 in government subsidies recognized in 2019, compared to CNY 23,008,046.04 in 2018[17]. - The company's total operating revenue for 2019 was approximately ¥1.43 billion, representing a 40.7% increase from ¥1.02 billion in 2018[36]. - The net profit attributable to shareholders was CNY 570.82 million, up 42.00% compared to the previous year[28]. Dividend Distribution - The company plans to distribute a cash dividend of 9.00 RMB per 10 shares (including tax) and to increase capital by converting 9 shares for every 10 shares held[3]. - The company plans to distribute a cash dividend of 9.00 yuan per 10 shares (including tax) for the 2019 fiscal year, with a total cash dividend amounting to 376,797,024.00 yuan[76]. - The cash dividend represents 66.01% of the net profit attributable to ordinary shareholders in the consolidated financial statements for 2019, which is 570,822,715.83 yuan[78]. - The total distributable profit for the year is reported at 971,156,800.19 yuan, with the cash dividend accounting for 100% of the profit distribution[76]. - The company has consistently increased its cash dividend over the past three years, with previous distributions of 6.00 yuan per 10 shares in 2018 and 3.50 yuan per 10 shares in 2017[78]. - The company has committed to maintaining a minimum cash dividend ratio of 20% during significant capital expenditure periods[76]. Research and Development - The company focuses on independent and collaborative research and development to enhance its core technology and product offerings[21]. - R&D investment for the reporting period was 68.45 million RMB, accounting for 4.78% of total revenue, with a year-on-year growth of 48.36%[26]. - The company holds a total of 190 authorized patents, including 41 invention patents, with 16 new patents granted during the reporting period[26]. - The company invested 68.4516 million yuan in R&D, an increase of 48.36% year-on-year, and obtained 16 new patents during the reporting period[30]. - The company is focusing on research and development for new products, aiming to enhance its competitive edge in the market[193]. Market Presence and Strategy - The company has established a presence in over 5,000 secondary and higher-level hospitals across the country, indicating a growing brand influence[19]. - The company has established a marketing network covering over 5,000 hospitals nationwide[28]. - The company plans to deepen its marketing strategy in the blood purification field, focusing on expanding the market for blood perfusion applications, particularly in nephrology and hepatology[70]. - The company aims to enhance its brand image through various academic activities and direct communication with healthcare professionals and patients[22]. - The company is actively involved in clinical research to validate the effectiveness of its products in improving patient outcomes[28]. Production and Operations - The company has established several subsidiaries, including Zhuhai Janke Medical Materials Co., Ltd. and Zhuhai Jianqiang Medical Equipment Co., Ltd., to enhance its market presence[6]. - The company has developed over 300 process documents and nearly 200 quality control documents to ensure product quality in compliance with national standards[22]. - The company has established a professional academic promotion team of over 900 members to enhance its marketing efforts[26]. - The company has established an automated production workshop for blood perfusion devices, with an annual production capacity of 5 million units, potentially generating an annual output value of 3 billion yuan[30]. - The company has implemented a quality management system since 2005, certified by ISO 13485[27]. Financial Health and Assets - The total assets at year-end included cash and cash equivalents of CNY 1,271,729,885.77, accounting for 50.98% of total assets[51]. - The company reported a net cash outflow from investing activities of CNY -197,124,583.93, an improvement of 22.67% from CNY -254,928,453.92 in 2018[48]. - The company received CNY 60,908,823.00 in financing activities, a 49.97% increase from CNY 40,614,000.00 in the previous year[48]. - The company’s total liabilities decreased slightly to ¥262,633,102.43 in 2019 from ¥278,898,618.83 in 2018, a reduction of about 5.8%[172]. - The company’s total equity attributable to shareholders reached ¥2,154,956,627.01 in 2019, up from ¥1,704,170,085.99 in 2018, indicating an increase of approximately 26.4%[177]. Corporate Governance - The company has established a complete independent financial department with a standardized financial accounting system, enabling independent financial decision-making and management[144]. - The company has a comprehensive internal control system, with 100% of the assets and revenue included in the internal control evaluation scope[153]. - The company has actively listened to and adopted the independent directors' suggestions regarding operational development and corporate governance[149]. - The board of directors consists of nine members, including three independent directors, ensuring a high level of governance and decision-making[142]. - The company maintains a transparent information disclosure process, ensuring all shareholders have equal access to information[143]. Risks and Challenges - The company emphasizes the importance of risk management in its operations, stating that there are no substantial risks affecting its production and operations during the reporting period[2]. - The company faces risks related to product quality control, product structure singularity, and potential declines in gross margin due to market competition[73]. - The company has recognized the need to adapt its management practices in response to rapid growth and increased operational scale[73]. - The company has a high gross margin, but it is vulnerable to market price fluctuations and competition dynamics that could impact profitability[73]. Employee and Management - The company employed a total of 1,895 staff, with 913 in sales, 427 in production, and 267 in technical roles[137]. - The total pre-tax remuneration for directors, supervisors, and senior management amounted to CNY 7.41 million[135]. - The company emphasizes employee training, establishing a comprehensive training system to improve overall capabilities and support business development[140]. - The company has added over 330 new talents, including approximately 160 marketing personnel and over 70 R&D staff, bringing the total number of employees to 1,895[31]. - The company has implemented two stock option incentive plans in 2019, covering nearly 600 employees, to enhance motivation and responsibility among the management team[31].